Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

It's thanks to these efforts that Exelixis' financial results have been solid. Revenue, earnings, and free cash flow have all ...

We take a look at Oxford’s biotech and life sciences hub to discover what makes this historical city a hotspot for scientific ...

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a ...

The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in ...

Titan Biotech shares surged 20% to ₹312 after a 1:5 stock split, enhancing liquidity and making shares more affordable for ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...